Cytogenetic manifestations of multiple myeloma heterogeneity

Genes Chromosomes and Cancer

Volumn 42, Issue 1, 2005, Pages 44-57

  Pantou, Dimitra ^a   Rizou, Helen ^a   Tsarouha, Haroula ^a   Pouli, Anastasia ^a   Papanastasiou, Kostas ^a   Stamatellou, Marina ^a   Trangas, Theoni ^a   Pandis, Nikos ^a   Bardi, Georgia ^a  

^a G Papanicolaou Research Center for Oncology   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME MARKER; CHROMOSOME NUMBER; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INTERPHASE; KARYOTYPE; MAJOR CLINICAL STUDY; METAPHASE; MOLECULAR CLONING; MULTIPLE MYELOMA; PATHOLOGY; PRIORITY JOURNAL; SAMPLING;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME BANDING; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

EID: 9644275520     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20114     Document Type: Article

References (28)

1. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp M-J, Harousseau J-L, Minvielle S, Bataille R. 2002. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191.
2. Bardi G, Johansson B, Pandis N, Bak-Jensen E, Orndal C, Heim S, Mandahl N, Andren-Sandberg A, Mitelman F. 1993. Cytogenetic aberrations in colorectal adenocarcinomas and their correlation to clinicopathologic features. Cancer 71:306-314.
3. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. 2004. Treatment of multiple myeloma. Blood 103:20-32.
4. Bataille R, Harousseau JL. 1997. Multiple myeloma. N Engl J Med 336:1657-1664.
5. Bergsagel PL, Kuehl WM. 2001. Chromosome translocations in multiple myeloma. Oncogene 20:5611-5622.
6. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. 1996. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93:13931-13936.
7. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Cuesta B, Gullon A. 1997. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84-93.
8. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. 2003. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17:427-436.
9. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. 2002. Myeloma and the t(11;14)(q13; q32); evidence for a biologically defined unique subset of patients. Blood 99:3735-41.
10. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. 2003. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575.
11. Heim S, Mandahl N, Mitelman F. 1988. Genetic convergence and divergence in tumor progression. Cancer Res 48:5911-5916.
12. ISCN. 1995. An international system for human cytogenetic nomenclature. Mitelman F, editor. Basel, Switzerland: S. Karger.
13. Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. 2000. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18:804-812.
14. Kuéhl WF and Bergsagel PL. 2002. Multiple myeloma: evolving genetic events and host interactions. Nature Reviews 2:177-192.
15. Kyle RA. 1992. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 6:347-358.
16. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. 1995. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497.
17. Mitelman F. 2004. Database of chromosome aberrations in cancer. Available at: http://cgap.nih.nci.gov/Chromosomes/Mitelman
18. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseou J-L, Bataille R, Avet-Loisseau H. 2002. Reccurent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:1579-1583.
19. Nilsson T, Lenhoff S, Turesson I, Rylander L, Mitelman F, Westin J, Höglund M, Johansson B. 2002. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. Eur J Haematol 68:345-353.
20. Nilsson T, Höglund M, Lenhoff S, Rylander L, Turesson I, Westin J, Mitelman F, Johansson B. 2003. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 20:960-969.
21. Pratt G. 2002. Molecular aspects of multiple myeloma. J Clin Pathol 55:273-283.
22. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RSK. 1998. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92:1743-1748.
23. Rasillo A, Tabernero MD, Sanchez ML, Perez de Andres M, Martin Ayuso M, Hernandez J, Moro MJ, Fernandez-Calvo J, Sayagues JM, Bortoluci A, San Miguel JF, Orfao A. 2003. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer 97:601-609.
24. Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, Gilliland JC, Munshi NC, Tricot G, Shaughnessy JD, Barlogie B. 2001. Multicolor spectral karyotype identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 112:167-174.
25. Shaughnessy JD and Barlogie B. 2003. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev 194:140-163.
26. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. 2001. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238.
27. Zandecki M, Lai JL, Genevieve F, Bernardi F, Volle-Remy H, Blanchet O, Francois M, Cosson A, Bauters F, Facon T. 1997. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood 90:3682-3690.
28. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Passas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757.